Active Ingredient History

  • Now
Dacarbazine (DTIC), also known as imidazole carboxamide, is an antineoplastic agent, which is used in the treatment of metastatic malignant melanoma. In addition, this drug also is indicated for Hodgkin’s disease as a second-line therapy when used in combination with other effective agents. Dacarbazine works by methylating guanine at the O-6 and N-7 positions. Guanine is one of the four nucleotides that makes up DNA. The alkylated DNA strands stick together such that cell division becomes impossible. This affects cancer cells more than healthy cells because cancer cells divide faster. Dacarbazine is bioactivated in liver by demethylation to "MTIC" and then to diazomethane, which is an alkylating agent. Symptoms of anorexia, nausea, and vomiting are the most frequently noted of all toxic reactions. Over 90% of patients are affected with the initial few doses.   NCATS

  • SMILES: CN(C)\N=N\C1=C(N=CN1)C(N)=O
  • Mol. Mass: 182.1832
  • ALogP: 0.07
  • ChEMBL Molecule:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$6.7500 - $16.3600
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

4-(3,3-dimethyl-1-triazeno)imidazole-5-carboxamide | 4-(5)-(3,3-dimethyl-1-triazeno)imidazole-5(4)-carboxamide | 4-(dimethyltriazeno)imidazole-5-carboxamide | 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide | 5-(3,3-dimethyltriazeno)imidazole-4-carboxamide | 5-(dimethyltriazeno)imidazole-4-carboxamide | biocarbazine | dacarbacine | dacarbazin | dacarbazina | dacarbazine | dacarbazinum | darcabazine | decarbazine | deticene | dic | dtci | dtic | dtic-dome | icdmt


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue